Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Professor Nancy Ip discusses her groundbreaking neuroscience research, focusing on neurotrophic factors and innovative ...

Dr. Philip Barber is a stroke and cognitive neurologist and Professor at the University of Calgary. He directs the Stroke ...

Two enzymes in brain cells are responsible for mediating the toxic effects of certain fat molecules in multiple sclerosis, ...

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

Boca Raton, Florida, Nov. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s ...

As Alberta celebrates the end of coal-fired power in the province, let’s put the brakes on exporting this same dirty fuel ...

The most well-known is semaglutide, attributed with protective effects against neurodegeneration and neuroinflammation. The ...

*仅供医学专业人士阅读参考β淀粉样蛋白（Aβ）沉积是阿尔茨海默病（AD）的关键病理特征和主要治疗靶点。β淀粉样蛋白前体（APP）裂解酶1（BACE1）是Aβ生成的关键酶，之前的研究表明，AD患者的免疫系统可能出现异常，产生针对自身组织的抗体（例如BA ...

INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness ...

Millions of people around the world benefit from weight loss drugs based on the incretin hormone GLP-1. These drugs also improve kidney function, reduce the risk of fatal cardiac events, and are ...

BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and ...